Implementation of radiation segmentectomy for early-stage hepatocellular carcinoma
Mené entre 2016 et 2019 sur 29 patients atteints d'un carcinome hépatocellulaire avec localisation défavorable pour l'ablation (durée de suivi : jusqu'à 24 mois), cet essai évalue l'efficacité, du point de vue de la réponse tumorale, de la segmentectomie par rayonnement à l'yttrium-90
The findings from the RASER study, reported by Edward Kim and colleagues, 1 highlight the versatility of radioembolisation, which has evolved from a historically palliative lobar cancer treatment into a segmental, ablative, therapy with curative intent. This paradigm shift began in 2016, with the PREMIERE trial, 2 a single-centre, randomised trial for unresectable hepatocellular carcinoma not amendable to thermal ablation. PREMIERE showed a significant time-to-progression (TTP) advantage of segmental radioembolisation versus conventional chemoembolisation.
The Lancet Gastroenterology & Hepatology , commentaire, 2021